act like expert veterinarian and tell me the treatment protocol with drug and dosage for seizure in dogs in detail
Reading File
Searching the Web
canine seizure treatment protocol drug dosage veterinary 2024 guidelines
Searching PubMed
"dogs" AND "seizures" AND "antiepileptic"
Canine Seizure Management Protocol
Based on the 2024 ACVIM Consensus Statement on status epilepticus/cluster seizures and the 2015 ACVIM Consensus Statement on chronic seizure management in dogs.
1. Initial Triage - Classify Before Treating
| Presentation | Definition | Urgency |
|---|---|---|
| Single seizure | One event, dog recovers | Non-emergency, diagnostic workup |
| Cluster seizures | ≥2 seizures within 24h | Urgent, needs rescue meds |
| Status epilepticus (SE) | Seizure >5 min, or repeated seizures without full recovery between | True emergency |
First actions on any actively seizing dog: protect airway, check glucose (treat if <60 mg/dL with dextrose), check temperature (cool if hyperthermic >41°C from prolonged motor activity), IV access, and monitor for aspiration.
2. Emergency (In-Hospital) Protocol for Active Seizures/Status Epilepticus
First-line - Benzodiazepines
- Diazepam: 0.5-1 mg/kg IV (or 1-2 mg/kg PR/intranasal if no IV access), may repeat x2-3 at 5-10 min intervals
- Midazolam: 0.2-0.3 mg/kg IV, IM, or intranasal (preferred over diazepam for IM/IN routes since it's water-soluble and absorbs reliably)
If seizures continue after 2-3 benzodiazepine doses → second-line loading agents
Second-line
- Phenobarbital: 2-4 mg/kg IV bolus, may repeat to a cumulative loading dose of 16-20 mg/kg over 24h
- Levetiracetam: 30-60 mg/kg IV (given over 5 min or as short infusion), can repeat
- Fosphenytoin: 15-20 mg PE/kg IV (less commonly available)
Refractory status epilepticus (continues despite the above) - third-line, ICU-level care
- Constant rate infusions (CRI):
- Midazolam CRI: 0.1-0.5 mg/kg/h IV after a loading dose
- Propofol CRI: 0.1-0.6 mg/kg/min IV (bolus 1-4 mg/kg to effect, then CRI), requires ventilatory support monitoring
- Ketamine CRI: 0.5-2 mg/kg/h as an add-on (NMDA antagonist, addresses receptor trafficking in prolonged SE)
- Inhalant anesthesia (isoflurane) as a last resort in a fully monitored/ventilated patient
3. Out-of-Hospital / Home Rescue Protocol for Cluster Seizures
For owners managing a dog with known epilepsy who has cluster seizures at home:
- Diazepam rectal gel: 0.5-2 mg/kg PR at seizure onset, may repeat once in 4-6h if needed (max recommended per episode per label guidance)
- Midazolam intranasal: 0.2 mg/kg IN - increasingly preferred over rectal diazepam because it's easier for owners to administer and absorbs quickly across nasal mucosa
- If seizures recur despite 2 doses of rescue benzodiazepine within 24h, the dog should be brought in for IV-level care
4. Chronic Maintenance Antiepileptic Drug (AED) Therapy
When to start: After ≥2 unprovoked seizures within a 6-month period, any cluster seizure event, status epilepticus, or severe post-ictal signs.
First-line maintenance drugs
| Drug | Starting Dose | Target Trough Level | Notes |
|---|---|---|---|
| Phenobarbital | 2.5-3 mg/kg PO q12h | 20-35 µg/mL (check at 2 weeks) | Hepatotoxic with chronic use - monitor liver enzymes/bile acids q6 months |
| Potassium/Sodium Bromide | 20-25 mg/kg/day PO (loading: 400-600 mg/kg divided over 1-5 days if urgent) | 1-3 mg/mL (monotherapy higher end, 0.8-2.5 mg/mL with phenobarbital) | Long half-life (~15-25 days), avoid in cats (bronchitis risk), caution in renal disease |
| Levetiracetam | 20 mg/kg PO q8h (immediate release) or 30 mg/kg PO q12h for extended-release | 5-45 µg/mL (less critical to monitor) | Minimal hepatic metabolism, good add-on or first-line in hepatic-impaired dogs, "honeymoon effect" may wane over months |
Second-line / add-on drugs (for drug-resistant epilepsy - roughly 20-30% of dogs)
- Zonisamide: 5-10 mg/kg PO q12h (start lower, ~3-5 mg/kg, if combined with phenobarbital due to induced clearance)
- Gabapentin: 10-20 mg/kg PO q8h (adjunct, mild efficacy, useful for concurrent pain/anxiety)
- Pregabalin: 2-4 mg/kg PO q8-12h
- Imepitoin: 10-30 mg/kg PO q12h (licensed in Europe as a first-line option; low-affinity partial benzodiazepine receptor agonist, fewer hepatic/sedative side effects)
- Cannabidiol (CBD): emerging adjunct evidence (2.5 mg/kg PO q12h in some trials) - efficacy still inconsistent per recent systematic review; not a substitute for licensed AEDs
5. Monitoring Protocol
- Baseline before starting phenobarbital/bromide: CBC, chemistry panel (liver values, bile acids), consider T4 if hypothyroid suspected
- Phenobarbital: serum trough level at 2 weeks after starting/dose change, then q6 months; liver panel q6 months
- Bromide: serum level at 1 month (or sooner if loaded), then q3-6 months
- Body condition/weight - both phenobarbital and bromide cause weight gain and PU/PD/PP
- Seizure diary - the therapeutic goal is a tripling of the inter-seizure interval sustained for at least 3 months, not necessarily complete freedom from seizures
6. Concurrent Workup (don't treat symptomatically without ruling out cause)
- Bloodwork/bile acids to rule out metabolic causes (hepatic encephalopathy, hypoglycemia, electrolyte disturbance)
- MRI brain + CSF analysis if seizures start outside the typical idiopathic epilepsy age window (6 months-6 years), if interictal neuro deficits are present, or if seizures are refractory to first-line AEDs
- Idiopathic epilepsy is a diagnosis of exclusion
Key Sources
- Charalambous M, et al. ACVIM Consensus Statement on the management of status epilepticus and cluster seizures in dogs and cats. J Vet Intern Med. 2024;38(1):19-40.
- 2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs
- Emergency Approach to Acute Seizures in Dogs and Cats, Vet Sci. 2024
- Merck Veterinary Manual - Epilepsy in Small Animals
Important caveat: A recent 2025 systematic review (PMID: 40829476) found risk-of-bias concerns in cannabidiol trials for refractory canine epilepsy - treat CBD as an unproven adjunct, not a reliable monotherapy.
Practical note: All dosages above are general reference points from consensus literature - actual dosing must be individualized based on the specific patient's weight, hepatic/renal function, concurrent drugs (many AEDs interact via hepatic enzyme induction/inhibition), and serum drug monitoring. This information is for veterinary professional reference and should not replace direct clinical judgment or consultation with a veterinary neurologist for refractory cases.
This is a shared conversation. Sign in to Orris to start your own chat.